VLP-Based Antibody-Inducing Vaccines for HIV-1
VLP-Based Antibody-Inducing Vaccines for HIV-1
批准号:
7845275
负责人:
Robert G. Whalen
金额:
$29.98万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-08-16 至 2012-07-31
关键词:
AIDS/HIV problemAddressAnimalsAntibodiesAntibody FormationAntigensAutologousBindingCapsidCellular MembraneCessation of lifeClinicalClinical TrialsComplexDissociationEpidemicEpitopesFailureGeneticGlycoproteinsHIVHIV Envelope Protein gp120HIV-1HIV-1 vaccineHepatitis B VirusImmunizationIn VitroInfectionInfection preventionLengthLifeLigandsMeasuresMembraneNatureOryctolagus cuniculusPatientsPhasePhysiologicalPrimatesProcessProductionPropertyPublic HealthRecombinantsRelative (related person)ResearchResearch ProposalsSmall Business Innovation Research GrantStructureSurfaceSurface AntigensT-LymphocyteVaccinesViralViral Envelope ProteinsVirusVirus-like particleVisionWorkbasedesignenv Gene Productsgag Gene Productsgp160immunogenicimmunogenicityimprovedneutralizing antibodyneutralizing monoclonal antibodiesnonhuman primateparticlepolypeptidepreventpublic health relevancevaccine candidatevaccine development
中文摘要
描述(由申请人提供):HIV-1流行病在2007年导致约270万新感染,共有约3300万艾滋病毒/艾滋病感染者。临床试验表明,HIV-1感染不能通过用病毒包膜(Env)蛋白的单体重组形式免疫来预防。然而,很明显,HIV-1 Env含有可以诱导中和抗体的表位,并且这种抗体可以保护灵长类动物免受感染。
HIV-1 Env是一种跨膜糖蛋白。Env的外部亚基(gp 120)和膜近端外部区域(位于gp 41亚基内)都含有表位,这些表位是从感染患者分离的广泛中和单克隆抗体(mAb)的靶标。已经投入相当大的努力来产生可溶形式的Env三聚体。这些分子相对于单体gp 120的免疫原性的改善充其量是有限的。
产生改进的基于Env的免疫原的另一种方法是产生病毒样颗粒(VLP)。VLP是多价的,并且通常具有很强的免疫原性。全长HIV-1 Env蛋白可呈递在由Gag蛋白和细胞膜组分组成的VLP表面。这些VLP结构具有代表Env三聚体尖峰的真实模拟物的潜力。
必须克服几个挑战,以创建基于VLP的HIV-1疫苗。它们必须在高水平上生产。每个VLP上的Env分子的数量必须最大化。gp 160 Env多肽的加工必须在不解离gp 120亚基的情况下进行,以产生Env三聚体的功能形式。还可能需要使可变序列的免疫原性最小化。
在关于产生携带HIV-1 Env蛋白的VLP的初步研究中,我们已经开始解决上述挑战。初步结果是令人鼓舞的,并提供了一个基础,更详细的工作,准备VLP为基础的免疫原作为候选人的HIV-1疫苗。目的是创建携带Env蛋白的VLP,其形式最类似于病毒的功能性Env三聚体的当前视觉。
该I期SBIR提案的具体目的如下:(1)制备用于VLP生产的优化Env构建体;(2)制备具有不同Env序列的VLP构建体;和(3)评价各种VLP在兔中诱导中和抗体的能力
如果基于VLP的Env免疫原被证明在诱导中和抗体的能力方面上级可溶性gp 120或gp 140构建体,那么额外的研究将形成II期SBIR提案的基础。
公共卫生相关性:2007年,艾滋病毒/艾滋病流行病导致200万人死亡,270万人新感染,使艾滋病毒/艾滋病感染者总数接近3 300万人。研制疫苗被认为是减缓这一流行病所需的公共卫生措施的一个重要组成部分。这项研究计划旨在创造一种疫苗,可以诱导能够预防艾滋病毒感染的抗体。
英文摘要
DESCRIPTION (provided by applicant): The HIV-1 epidemic has resulted in ~2.7 million new infections in 2007 for a total of ~33 million people living with HIV/AIDS. Clinical trials have shown that HIV-1 infection cannot be prevented by immunization with monomeric recombinant forms of viral envelope (Env) proteins. However, it is clear that the HIV-1 Env contains epitopes that can induce neutralizing antibodies and that such antibodies can protect primates from infection.
The HIV-1 Env is a transmembrane glycoprotein. Both the external subunit (gp120) and the membrane- proximal external region of Env (located within the gp41 subunit) contain epitopes that are the target of broadly neutralizing monoclonal antibodies (mAbs) isolated from infected patients. Considerable effort has been devoted to creating soluble forms of the Env trimer. The improvements in immunogenicity of these molecules relative to monomeric gp120 are limited at best.
Another approach to creating improved Env-based immunogens is to produce virus-like particles (VLP). VLPs are multivalent and often very immunogenic. The full-length HIV-1 Env protein can be presented on the surface of VLPs composed of Gag protein and cellular membrane components. These VLP structures have the potential to represent true mimics of the Env trimer spike.
Several challenges must be overcome to create HIV-1 vaccines based on VLPs. They must be produced at high levels. The number of Env molecules on each VLP must be maximized. Processing of the gp160 Env polypeptide must take place, without dissociation of the gp120 subunit, to create a functional form of the Env trimer. It might also be necessary to minimize the immunogenicity of the variable sequences.
In preliminary studies on the creation of VLPs carrying HIV-1 Env proteins, we have begun to address the challenges outlined above. The preliminary results are encouraging and provide a basis for more detailed work on preparing VLP-based immunogens as candidates for HIV-1 vaccines. The objective is to create VLPs that carry the Env protein in a form that most resembles the current vision of the functional Env trimer of the virus.
The Specific Aims of this Phase I SBIR proposal are as follows: (1) prepare optimized Env constructs for VLP production; (2) prepare VLP constructs with different Env sequences; and (3) evaluate the ability of various VLPs to induce neutralizing antibodies in rabbits
If the VLP-based Env immunogens prove to be superior to soluble gp120 or gp140 constructs in their ability to induce neutralizing antibodies, then additional studies will form the basis of a Phase II SBIR proposal.
PUBLIC HEALTH RELEVANCE: The HIV/AIDS epidemic has resulted in 2 million deaths and 2.7 million new infections in 2007, for a total of nearly 33 million people living with HIV/AIDS. Development of a vaccine is considered to be an essential component of the public health measures needed to slow the epidemic. This research proposal is designed to create a vaccine that can induce antibodies capable of preventing infection by the HIV virus.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Therapeutic Vaccines for Chronic HBV
-
批准号:8394626
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2012
-
负责人:Robert G. Whalen
-
依托单位:
Novel Tetravalent Vaccines for Dengue Virus
-
批准号:8315393
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2012
-
负责人:Robert G. Whalen
-
依托单位:
Germline-Specific Immunogens for the Induction of Neutralizing Antibodies to HIV-
-
批准号:8329484
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2012
-
负责人:Robert G. Whalen
-
依托单位:
Germline-Specific Immunogens for the Induction of Neutralizing Antibodies to HIV-
-
批准号:8410439
-
项目类别:
-
资助金额:$59.78万
-
财政年份:2012
-
负责人:Robert G. Whalen
-
依托单位:
Germline-Specific Immunogens for the Induction of Neutralizing Antibodies to HIV-
-
批准号:8501370
-
项目类别:
-
资助金额:$55.15万
-
财政年份:2012
-
负责人:Robert G. Whalen
-
依托单位:
Novel Therapeutic Vaccines for Chronic HBV
-
批准号:8550764
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2012
-
负责人:Robert G. Whalen
-
依托单位:
Novel Tetravalent Vaccines for Dengue Virus
-
批准号:8534703
-
项目类别:
-
资助金额:$29.85万
-
财政年份:2012
-
负责人:Robert G. Whalen
-
依托单位:
Germline-Specific Immunogens for the Induction of Neutralizing Antibodies to HIV-
-
批准号:8502420
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2012
-
负责人:Robert G. Whalen
-
依托单位:
Germline-Specific Immunogens for the Induction of Neutralizing Antibodies to HIV-
-
批准号:8704267
-
项目类别:
-
资助金额:$84.07万
-
财政年份:2012
-
负责人:Robert G. Whalen
-
依托单位:
Improved Vaccines for Influenza B Virus
-
批准号:8007330
-
项目类别:
-
资助金额:$29.84万
-
财政年份:2010
-
负责人:Robert G. Whalen
-
依托单位:
VLP-Based Antibody-Inducing Vaccines for HIV-1
-
批准号:8129654
-
项目类别:
-
资助金额:$29.99万
-
财政年份:2010
-
负责人:Robert G. Whalen
-
依托单位:
Designing Improved HIV-1 Envelope Proteins as Vaccine Candidates
-
批准号:8129629
-
项目类别:
-
资助金额:$29.93万
-
财政年份:2010
-
负责人:Robert G. Whalen
-
依托单位:
Designing Improved HIV-1 Envelope Proteins as Vaccine Candidates
-
批准号:7931360
-
项目类别:
-
资助金额:$29.98万
-
财政年份:2010
-
负责人:Robert G. Whalen
-
依托单位:
Improved Vaccines for Influenza B Virus
-
批准号:8082724
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2010
-
负责人:Robert G. Whalen
-
依托单位:
Novel Vaccine Immunogens for Pandemic H5 Influenza
-
批准号:7538182
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2008
-
负责人:Robert G. Whalen
-
依托单位:
Novel Vaccine Immunogens for Pandemic H5 Influenza
-
批准号:7671507
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2008
-
负责人:Robert G. Whalen
-
依托单位:
Novel gp41 Immunogens for HIV-1 Vaccines
-
批准号:7477233
-
项目类别:
-
资助金额:$29.87万
-
财政年份:2007
-
负责人:Robert G. Whalen
-
依托单位:
Novel gp41 Immunogens for HIV-1 Vaccines
-
批准号:7339514
-
项目类别:
-
资助金额:$29.67万
-
财政年份:2007
-
负责人:Robert G. Whalen
-
依托单位:
Creation of Stable Cleaved Trimers of the HIV-1 Envelope Protein
-
批准号:7120976
-
项目类别:
-
资助金额:$24.04万
-
财政年份:2006
-
负责人:Robert G. Whalen
-
依托单位:
Vaccines for Eastern and Western Equine Encephalitis Viruses
-
批准号:7276764
-
项目类别:
-
资助金额:$50.28万
-
财政年份:2006
-
负责人:Robert G. Whalen
-
依托单位:
海外基金